腫瘍学セグメントはマイクロバイオームシーケンシングサービス市場で主要な市場シェアを保持することが期待されています

• 1 イントロダクション

  • 1.1 調査の前提条件と市場の定義

  • 1.2 本調査の範囲

• 2 調査手法

• 3 エグゼクティブサマリー

• 4 市場力学

  • 4.1 市場概要

  • 4.2 市場の促進要因

  • 4.3 市場の抑制要因

    • 4.3.1 ゲノム解読に関わる倫理的・法的問題

    • 4.3.2 NGSデータ解析のための熟練技術者の不足

  • 4.4 ポーターのファイブフォース分析

    • 4.4.1 新規参入の脅威

    • 4.4.2 買い手・消費者の交渉力

    • 4.4.3 サプライヤーの交渉力

    • 4.4.4 代替品の脅威

    • 4.4.5 競合・競争状況の激しさ

• 5 市場セグメント別（金額別市場規模　-　USD　Millions）

  • 5.1 技術別

    • 5.1.1 ライゲーションによる配列決定（SBL）

    • 5.1.2 シーケンシング・バイ・シンセシス(SBS)

    • 5.1.3 ショットガンシーケンス

    • 5.1.4 ターゲット遺伝子配列決定

    • 5.1.5 その他の技術

  • 5.2 用途別

    • 5.2.1 消化器系疾患

    • 5.2.2 感染症

    • 5.2.3 中枢神経系疾患

    • 5.2.4 オンコロジー

    • 5.2.5 その他の用途

  • 5.3 地域別

    • 5.3.1 北米

      • 5.3.1.1 米国
      • 5.3.1.2 カナダ
      • 5.3.1.3 メキシコ

    • 5.3.2 ヨーロッパ

      • 5.3.2.1 ドイツ
      • 5.3.2.2 英国
      • 5.3.2.3 フランス
      • 5.3.2.4 イタリア
      • 5.3.2.5 スペイン
      • 5.3.2.6 その他ヨーロッパ

    • 5.3.3 アジア太平洋

      • 5.3.3.1 中国
      • 5.3.3.2 日本
      • 5.3.3.3 インド
      • 5.3.3.4 オーストラリア
      • 5.3.3.5 韓国
      • 5.3.3.6 その他アジア太平洋

    • 5.3.4 中東・アフリカ

      • 5.3.4.1 GCC地域
      • 5.3.4.2 南アフリカ
      • 5.3.4.3 その他中東・アフリカ

    • 5.3.5 南米

      • 5.3.5.1 ブラジル
      • 5.3.5.2 アルゼンチン
      • 5.3.5.3 その他南米

• 6 競合情勢

  • 6.1 企業プロファイル

    • 6.1.1 Baseclear BV

    • 6.1.2 Clinical Microbiomics AS

    • 6.1.3 Merieux Nutrisciences Corporations

    • 6.1.4 Locus Biosciences (EPIBIOME)

    • 6.1.5 Microbiome Insights Inc

    • 6.1.6 Microbiome Therapeutics LLC

    • 6.1.7 MR DNA

    • 6.1.8 Second Genome

    • 6.1.9 uBiome

    • 6.1.10 Zymo Research

    • 6.1.11 Rancho Biosciences

    • 6.1.12 Metabiomics

• 7 市場機会と今後の動向

The Microbiome Sequencing Services Market is projected to register a CAGR of 9.2% during the forecast period (2022 - 2027).

During the COVID-19 pandemic, several studies were focused on the impact of the SARS-CoV-2 virus on the health of the human population. The microbiome sequencing services have extensively helped in studying the COVID-19 impact on the human microbiome. An article titled “The Unique Impact of COVID-19 on Human Gut Microbiome Research,” published in the journal of Frontiers in Medicine in March 2021, explores the direct and indirect influences of the pandemic on the gut microbiome and how these can affect research and clinical trials. The study showed an extensive interaction between the gut microbiome and the SARS-CoV-2 virus. The disrupted gut microbiome contributed to the course and severity of COVID-19, as the loss of beneficial microbes, the proliferation of potentially harmful microbes, and the reduction of microbial diversity contributed to the worsening health. The microbiome sequencing services have largely helped the research by studying the gut microbiome at varying stages of infection. Thus, the increased use of microbiome sequencing services during the COVID-19 pandemic is likely to add to the growth of the market.

The increasing demand for Next-Generation Sequencing is a major factor attributing to the growth of the microbiome sequencing services market. An article titled “Bioinformatics and Computational Tools for Next-Generation Sequencing Analysis in Clinical Genetics,” published in the Journal of Clinical Medicine in January 2020, indicated that Next-generation sequencing (NGS) had transformed clinical genetics, making it possible to analyze hundreds of genes at an unprecedented speed and at a lower price than other conventional sequencing methods. According to the article, developments in machine learning algorithms such as neural networks and support vector machines, along with the innovations in the artificial intelligence field, largely help in the development of novel tools for integrated sequencing system levels. Such innovations in the Next Generation Sequencing services are expected to boost the growth of the microbiome sequencing services market.

The rise in genomic research all over the world is also contributing to the growth of the microbiome sequencing services market in the forecast period. The National Human Genome Research Institute of the United States National Institute of Health data on Genomic Data Science updated in April 2022 indicated that as biomedical research projects and large-scale collaborations grow rapidly, the amount of genomic data being generated is also increasing, with roughly 2 to 40 billion gigabytes of data being generated every year. A large number of research and development projects in genomic research are adding to the growth of the microbiome sequencing services market.

Also, in June 2021, Illumina and Microba Life Sciences launched a partnership to improve the understanding of the human gut microbiome in human health and diseases. The partnership will combine Illumina’s revolutionary NGS tools and Microba’s high-quality proprietary gut microbiome analysis platform to produce the accurate metagenomic data required by researchers to fuel new discoveries. Such research collaborations are also adding to the growth of the studied market.

However, ethical and legal issues related to genome sequencing and the lack of skilled technicians for NGS data analysis are hindering the growth of the microbiome sequencing services market in the forecast period.

Key Market Trends

The Oncology Segment is Expected to Hold a Major Market Share in the Microbiome Sequencing Services Market

Oncology holds the major segment in the Microbiome Sequencing Services market. The rising number of cancer cases all over the world and the increasing cancer genomic research is expected to boost the growth of the microbiome sequencing services market. An article titled “The promise and challenge of cancer microbiome research” published in the journal of Genome Biology in June 2020 focused on the multifaceted role of the human microbiome on the cancer onset, development, detection, treatment, and outcome. The article implied that a certain majority of cancer cases were attributed to microbial action and that a microbe can have both tumor-suppressing and tumor-inducing factors, which could be understood with further studies on microbiome and cancer. The increasing number of studies focusing on the effects of the microbiome on cancer are boosting the growth of the oncology segment in the microbiome sequencing services market in the forecast period.

The rising number of cancer cases around the world is also adding to the developments in the microbiome sequencing services market. According to the Globocan 2020 report, the number of cancer cases in the year 2020 is 19,292,789, and the numbers are estimated to rise to 28,887,940 cases by 2040. The large increase in the number of cases over the years is majorly contributing to the increase in cancer genomic research for efficient treatment studies, which in turn will propel the growth of the microbiome sequencing services market in the forecast period.

According to an article titled “Clinical Validation of Whole Genome Sequencing for Cancer Diagnostics,” published in the journal of Molecular Diagnostics in July 2021, whole genome sequencing (WGS) using fresh-frozen tissue and matched blood samples from cancer patients might become the most complete genetic tumor test. The article indicated that with the increasing necessity for a large number of small biomarker studies, a single all-inclusive test is usually prefered over conventional test methods. The whole genome sequencing had more than 95% specificity and sensitivity to other methods in the cancer DNA diagnostic techniques, which is boosting the growth of the oncology segment in the microbiome sequencing services market in the forecast period.

The research and development by key market players in the segment are also adding to the market growth. For instance, in March 2022, Microbiotica raised USD 67 million for its research on microbiome-based immuno-oncology through phase 1b trials, which are to be started later in the year. Such contributions by the market players are expected to propel market growth.

The rising research on cancer diagnostics and therapy with the help of sequencing services is adding to the growth of the microbiome sequencing services market in the study period.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same Over the Forecast Period

The rise in the adoption of highly advanced techniques and systems in the microbiome sequencing services and the technological advancements made in genomic research studies is expected to boost the growth of the market in the North American region. The high awareness among the healthcare personnel on the availability of innovative microbiome sequencing services in the market contributes to the high market growth in the region.

The rising number of cancer cases in the North American region is adding to the growth of the microbiome sequencing services market.​ Cancer is one of the top ten leading causes of death in the United States. According to the GLOBOCAN 2020 report, the total number of people in the United States affected by cancer in 2020 accounts for around 2,281,658 cases. The number is estimated to rise to 3,123,452 cases by 2040. ​The large population affected by cancer and the increase in the necessity of microbiome sequencing services for the ease of diagnosis and treatment of such diseases is expected to propel the growth of the microbiome sequencing services market in the forecast period.

​ Researchers from Rutgers University, United States, in their article titled “Guild-based analysis for understanding gut microbiome in human health and diseases” in the journal of Genome Medicine in February 2021, discussed the use of a guild to identify potentially important functional microbiome associated with specific health outcomes and disease phenotypes through next-generation sequencing. The article suggested that guild-based analysis may create a paradigm shift toward an ecologically meaningful approach to understanding the relationship between the gut microbiome and human health. The rise in the research studies on the microbiome through the use of sequencing services in the United States is likely to add to the growth of the studied market over the forecast period.

In May 2022, the Institute for Food Safety and Health held a symposium titled “2022 IFSH Virtual High-Throughput Sequencing (HTS) Symposium”, wherein the profound impacts of High Throughput or Next Generation Sequencing were discussed. The symposium stated that the adoption of such sequencing services by the governmental agencies in the United States had resulted in an upgrade in the knowledge, experience, and infrastructure for the development of a safer food safety system in the region. Such developments are adding to the growth of microbiome sequencing services in the United States region.

Thus the increasing necessity for microbiome sequencing services coupled with increasing investment in the health care department is known to propel the growth of the market in this region.

Competitive Landscape

The global microbiome sequencing services market is moderately competitive and consists of a number of major players. Companies like Baseclear BV, Clinical Microbiomics AS, Merieux Nutrisciences Corporations, EPIBIOME, Microbiome Insights Inc., Microbiome Therapeutics LLC, MR DNA, Second Genome, Ubiome Inc., and Zymo Research Corp., among others, hold substantial shares in the microbiome sequencing services market.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

• 1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition

  • 1.2 Scope of the Study

• 2 RESEARCH METHODOLOGY

• 3 EXECUTIVE SUMMARY

• 4 MARKET DYNAMICS

  • 4.1 Market Overview

  • 4.2 Market Drivers

    • 4.2.1 Huge Investment in Microbiome Research

    • 4.2.2 Rise in Demand for NGS Services

    • 4.2.3 Surge in Genomic Research and Widening Application Area of Microbiome Sequencing

  • 4.3 Market Restraints

    • 4.3.1 Ethical and Legal Issues Related to Genome Sequencing

    • 4.3.2 Lack of Skilled Technicians for NGS Data Analysis

  • 4.4 Porter's Five Forces Analysis

    • 4.4.1 Threat of New Entrants

    • 4.4.2 Bargaining Power of Buyers/Consumers

    • 4.4.3 Bargaining Power of Suppliers

    • 4.4.4 Threat of Substitute Products

    • 4.4.5 Intensity of Competitive Rivalry

• 5 MARKET SEGMENTATION (Market Size by Value - USD Millions)

  • 5.1 By Technology

    • 5.1.1 Sequencing by Ligation (SBL)

    • 5.1.2 Sequencing by Synthesis (SBS)

    • 5.1.3 Shotgun Sequencing

    • 5.1.4 Targeted Gene Sequencing

    • 5.1.5 Other Technologies

  • 5.2 By Application

    • 5.2.1 Gastrointestinal Diseases

    • 5.2.2 Infectious Diseases

    • 5.2.3 CNS Diseases

    • 5.2.4 Oncology

    • 5.2.5 Other Applications

  • 5.3 Geography

    • 5.3.1 North America

      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico

    • 5.3.2 Europe

      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe

    • 5.3.3 Asia-Pacific

      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific

    • 5.3.4 Middle-East and Africa

      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa

    • 5.3.5 South America

      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

• 6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles

    • 6.1.1 Baseclear BV

    • 6.1.2 Clinical Microbiomics AS

    • 6.1.3 Merieux Nutrisciences Corporations

    • 6.1.4 Locus Biosciences (EPIBIOME)

    • 6.1.5 Microbiome Insights Inc

    • 6.1.6 Microbiome Therapeutics LLC

    • 6.1.7 MR DNA

    • 6.1.8 Second Genome

    • 6.1.9 uBiome

    • 6.1.10 Zymo Research

    • 6.1.11 Rancho Biosciences

    • 6.1.12 Metabiomics

• 7 MARKET OPPORTUNITIES AND FUTURE TRENDS